6dif
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==Wild-type HIV-1 protease in complex with tipranavir== | |
| + | <StructureSection load='6dif' size='340' side='right' caption='[[6dif]], [[Resolution|resolution]] 1.20Å' scene=''> | ||
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>[[6dif]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6DIF OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6DIF FirstGlance]. <br> | ||
| + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=TPV:N-(3-{(1R)-1-[(6R)-4-HYDROXY-2-OXO-6-PHENETHYL-6-PROPYL-5,6-DIHYDRO-2H-PYRAN-3-YL]PROPYL}PHENYL)-5-(TRIFLUOROMETHYL)-2-PYRIDINESULFONAMIDE'>TPV</scene></td></tr> | ||
| + | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[2ien|2ien]], [[6dil|6dil]], [[6dj1|6dj1]], [[6dj2|6dj2]]</td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6dif FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6dif OCA], [http://pdbe.org/6dif PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6dif RCSB], [http://www.ebi.ac.uk/pdbsum/6dif PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6dif ProSAT]</span></td></tr> | ||
| + | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Four HIV-1 protease (PR) inhibitors, clinical inhibitors lopinavir and tipranavir, and two investigational compounds 4 and 5, were studied for their effect on the structure and activity of PR with drug-resistant mutation L76V (PRL76V). Compound 5 exhibited the best K i value of 1.9 nM for PRL76V, whereas the other three inhibitors had K i values of 4.5-7.6 nM, 2-3 orders of magnitude worse than for wild-type enzymes. Crystal structures showed only minor differences in interactions of inhibitors with PRL76V compared to wild-type complexes. The shorter side chain of Val76 in the mutant lost hydrophobic interactions with Lys45 and Ile47 in the flap, and with Asp30 and Thr74 in the protein core, consistent with decreased stability. Inhibitors forming additional polar interactions with the flaps or dimer interface of PRL76V were unable to compensate for the decrease in internal hydrophobic contacts. These structures provide insights for inhibitor design. | ||
| - | + | Drug Resistance Mutation L76V Alters Nonpolar Interactions at the Flap-Core Interface of HIV-1 Protease.,Wong-Sam A, Wang YF, Zhang Y, Ghosh AK, Harrison RW, Weber IT ACS Omega. 2018 Sep 30;3(9):12132-12140. doi: 10.1021/acsomega.8b01683. Epub 2018, Sep 27. PMID:30288468<ref>PMID:30288468</ref> | |
| - | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
| - | + | </div> | |
| - | [[Category: Wang, Y | + | <div class="pdbe-citations 6dif" style="background-color:#fffaf0;"></div> |
| - | [[Category: Weber, I | + | == References == |
| - | [[Category: Wong-Sam, A | + | <references/> |
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Wang, Y F]] | ||
| + | [[Category: Weber, I T]] | ||
| + | [[Category: Wong-Sam, A E]] | ||
| + | [[Category: Antiviral agent]] | ||
| + | [[Category: Hiv drug resistance]] | ||
| + | [[Category: Hydrolase-hydrolase inhibitor complex]] | ||
| + | [[Category: Protein-inhibitor structure]] | ||
Revision as of 07:57, 17 October 2018
Wild-type HIV-1 protease in complex with tipranavir
| |||||||||||
